How would you manage a cT4N0 HER2- distal esophageal adenocarcinoma, CPS score 30, with good response to neoadjuvant chemo-RT on PET and residual disease on EGD in a patient who declines surgery?

There's really no good answer here. What one does is predicated largely on how much faith one has in the efficacy of nivolumab.

The benefit of adjuvant nivolumab in patients with locally advanced esophageal cancer who underwent trimodality therapy and had residual disease is of course based on the Ch...